Stephen O’Hara, CEO of OptiBiotix, commented: “We are pleased to announce this non-exclusive license agreement with Nutrilinea for the production and commercialisation of products containing OptiBiotix’s LP(LDL) (R) strain for the reduction of cholesterol and cardiovascular risk. We chose Nutrilinea due to its industry reputation, extensive European network, and record of doubling revenues in the last 12 months. We believe working with Nutrilinea, and similar partners around the world, provide the best opportunity of building LP(LDL) (R) into a global brand. We see this as another step in building revenues and market presence of LP(LDL) (R) as the ‘Intel’ inside a wide range of products, provided in different presentations and formulations, for cardiovascular health across both consumer and pharmaceutical markets around the world.”
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, has told DirectorsTalk that it has agreed to grant a non-exclusive license agreement to Nutrilinea for the production and commercialisation of products containing OptiBiotix’s LP(LDL) (R) strain in Europe with a view to maximising the financial return for both parties.
Nutrilinea has over 15 years’ experience in the design and development of customised formulations and presentations (capsules, tablets, sachets) for the supplement and pharmaceutical industry. Nutrilinea provides products to both national and international businesses in Europe and the USA, and is one of Europe’s fastest growing providers of food supplements, doubling revenues in the last 12 months to over EUR30m per annum.
Nutrilinea is based in Italy and has established an international reputation for providing innovative product formulations and presentations for different markets, including products containing some of the world’s best selling probiotic strains. Nutrilinea intends to produce proprietary formulations containing OptiBiotix’s LP(LDL) (R) strain developed to reduce cholesterol levels and blood pressure (CholBiome(TM)), and cardiovascular risk (CardioBiome(TM)). Under the terms of the agreement, Nutrilinea intends to produce, promote, market and commercialise OptiBiotix’s CholBiome(TM) and CardioBiome(TM) products to their European network with the aim of maximising the financial return for both parties.
This pre-launch agreement is another step in a business to business (B2B) strategy of bringing OptiBiotix’s science together with partner’s expertise and market reach to serve multiple consumer healthcare and pharmaceutical markets around the world.
